SCHEMBL3633960

SCHEMBL3633960

CCOC(=O)C(O)c1ccc(C)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
HIF1A Q16665 1/20 0.40
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
PIN1 Q13526 1/20 0.39
MAPT P10636 2/20 0.38
P2RX7 Q99572 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
FFAR1 O14842 1/20 0.36
POLB P06746 1/20 0.36
MMP8 P22894 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
GAA P10253 1/20 0.36
CASP1 P29466 1/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30441395 0.85 MMP8 (0.44) CYP1A2CYP2C9HIF1AKMT2AMEN1
SCHEMBL16286568 0.85 MMP8 (0.44) CYP1A2CYP2C9HIF1AKMT2AMEN1
SCHEMBL462432 0.84 CASP1 (0.51) CYP1A2CYP2C9HIF1AKMT2AMEN1
SCHEMBL10664684 0.83 KMT2A (0.48) KMT2AMEN1MAPTP2RX7TDP1
SCHEMBL10352342 0.83 OXTR (0.45) CYP1A2CYP2C9HIF1AKMT2AMEN1
SCHEMBL10349461 0.80 KDM4E (0.42) CYP1A2CYP2C9HIF1AKMT2AMEN1
SCHEMBL3636643 0.79 LMNA (0.47) KMT2AMAPTP2RX7HDAC1HDAC6
SCHEMBL10827291 0.79 SMN1; SMN2 (0.51) KMT2AMEN1MAPTMMP8SMN1; SMN2
SCHEMBL13557323 0.77 MEN1 (0.47) CYP1A2CYP2C9KMT2AMEN1PIN1
SCHEMBL27976601 0.76 NQO1 (0.50) CYP1A2KMT2AMEN1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R CYP1A2 4013/4885CYP2C9 3035/4885HIF1A 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.